Bristol-Myers Squibb (BMY) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $2.04
- EPS estimate
- $1.60
- EPS surprise
- +27.73%
- Revenue surprise
- +10.51%
- Revenue
- $13.0B
- Revenue estimate
- $11.7B
- Reported
- Jul 30, 2026
Bristol-Myers Squibb reported Q2 2026 results on July 30, 2026. Earnings per share came in at $2.04, ahead of the $1.60 estimate by 27.73%. Revenue was $13.0 billion, 10.51% above the $11.7 billion consensus. Compared with Q2 2025, EPS rose about 40% from $1.46 and revenue rose about 6% from $12.3 billion.
The longer record is shaped by one loss quarter. In Q1 2024, the company posted a loss of $4.40 per share, close to the expected loss of $4.41. That pulled annual EPS for 2024 down to $1.14, against $7.70 in 2022, $7.50 in 2023 and $6.15 in 2025. Revenue has been far steadier, at $45.0 billion to $48.3 billion a year. The first half of 2026 adds up to $3.62 per share, about 11% more than a year earlier. Q2 2026 set the revenue high in the table, while the EPS high was $2.07 in Q2 2024. Over the last 20 quarters, Bristol-Myers Squibb topped the EPS estimate 19 times. The only miss was Q2 2023, at 10.79% below.
The company reported Q3 between October 26 and October 31 in each of the past five years. That points to late October 2026 for the next report.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 30, 2026 | $1.60 | $2.04 | +27.73% | $13.0B | SEC |
| Q1 2026 | Apr 30, 2026 | $1.42 | $1.58 | +10.99% | $11.5B | SEC |
| Q4 2025 | Feb 5, 2026 | $1.23 | $1.26 | +2.79% | $12.5B | SEC |
| Q3 2025 | Oct 30, 2025 | $1.52 | $1.63 | +7.41% | $12.2B | SEC |
| Q2 2025 | Jul 31, 2025 | $1.09 | $1.46 | +33.79% | $12.3B | SEC |
| Q1 2025 | Apr 24, 2025 | $1.49 | $1.80 | +20.43% | $11.2B | SEC |
| Q4 2024 | Feb 6, 2025 | $1.46 | $1.67 | +14.13% | $12.3B | SEC |
| Q3 2024 | Oct 31, 2024 | $1.49 | $1.80 | +20.47% | $11.9B | SEC |
| Q2 2024 | Jul 26, 2024 | $1.62 | $2.07 | +27.81% | $12.2B | SEC |
| Q1 2024 | Apr 25, 2024 | −$4.41 | −$4.40 | +0.28% | $11.9B | SEC |
| Q4 2023 | Feb 2, 2024 | $1.55 | $1.70 | +9.42% | $11.5B | SEC |
| Q3 2023 | Oct 26, 2023 | $1.76 | $2.00 | +13.37% | $11.0B | SEC |
| Q2 2023 | Jul 27, 2023 | $1.96 | $1.75 | −10.79% | $11.2B | SEC |
| Q1 2023 | Apr 27, 2023 | $1.97 | $2.05 | +3.95% | $11.3B | SEC |
| Q4 2022 | Feb 2, 2023 | $1.73 | $1.82 | +5.41% | $11.4B | SEC |
| Q3 2022 | Oct 26, 2022 | $1.83 | $1.99 | +8.85% | $11.2B | SEC |
| Q2 2022 | Jul 27, 2022 | $1.77 | $1.93 | +8.99% | $11.9B | SEC |
| Q1 2022 | Apr 29, 2022 | $1.91 | $1.96 | +2.39% | $11.6B | SEC |
| Q4 2021 | Feb 4, 2022 | $1.80 | $1.83 | +1.88% | $12.0B | SEC |
| Q3 2021 | Oct 27, 2021 | $1.92 | $2.00 | +4.24% | $11.6B | SEC |
Quarterly revenue
Frequently asked questions
When did Bristol-Myers Squibb (BMY) last report earnings?
Bristol-Myers Squibb last reported on Jul 30, 2026, covering fiscal Q2 2026.
Did BMY beat earnings estimates?
Yes. Bristol-Myers Squibb reported EPS of $2.04 for Q2 2026 against a $1.60 estimate — a 27.73% beat.
How much revenue did BMY report last quarter?
Bristol-Myers Squibb reported $13.0B in revenue for Q2 2026, against a consensus estimate of $11.7B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.